American Academy of Neurology (AAN) Annual Meeting 2026 | iPharmaCenter

Roche’s BTK inhibitor fenebrutinib delivers strong efficacy in relapsing multiple sclerosis, opening up a potential multi‑billion‑dollar revenue opportunity for the company

Roche’s BTK inhibitor fenebrutinib has generated a third consecutive Phase III success in multiple sclerosis, strengthening its positioning as a potential first-in-class option across both relapsing and progressive forms of the disease.

What clinical benefits fenebrutinib show in clinical trials?

In the latest pivotal trial, FENhance 1, the oral agent cut the annualised relapse rate in relapsing MS by 51% versus teriflunomide over at least 96 weeks, mirroring the 59% relapse reduction previously reported in the sister study FENhance 2 and translating into an estimated relapse frequency of roughly one event every 17 years.

Both relapsing MS studies also showed significant decreases in MRI lesion activity and favourable trends across disability progression metrics, while the PPMS trial FENtrepid reported benefit on progression comparable to ocrelizumab, together suggesting a consistent impact on both inflammatory and neurodegenerative disease biology.

Across the relapsing MS programme, liver enzyme elevations were generally similar to the teriflunomide comparator; each of the two FENhance trials recorded a single Hy’s Law case, one in each treatment arm, both asymptomatic and resolving after drug discontinuation, and no additional Hy’s Law signals have emerged from the broader MS and autoimmune portfolio.

Mortality imbalances are under close review, with one death in the teriflunomide arm and eight deaths with varied causes and timings in the fenebrutinib arms across FENhance 1 and 2, prompting further analyses to clarify any potential relationship to treatment.

What is the mechanism of action of fenebrutinib?

Mechanistically, fenebrutinib is a highly selective, reversible, non‑covalent BTK inhibitor engineered to reach the central nervous system, where it modulates both peripheral B‑cell–driven acute inflammation and microglial activity implicated in chronic tissue damage, thereby attempting to bridge the gap between relapse control and long‑term disability protection.

FENhance 1 and 2 together enrolled nearly 1,500 adults with relapsing MS into multicentre, randomised, double‑blind, double‑dummy studies comparing twice‑daily oral fenebrutinib against once‑daily teriflunomide for a minimum of 96 weeks, with annualised relapse rate as the primary endpoint and a comprehensive secondary endpoint battery covering gadolinium‑enhancing T1 lesions, new and enlarging T2 lesions, and composite disability progression based on EDSS, timed 25‑foot walk, and nine‑hole peg test performance.

After completing the blinded phase, participants can transition into an open‑label extension in which all receive fenebrutinib, allowing longer‑term assessment of durability, safety profile, and effects on progression. Taken together, the convergent data from FENhance 1, FENhance 2, and FENtrepid bolster the argument that fenebrutinib could emerge as the first high‑efficacy oral, brain‑penetrant BTK inhibitor with robust evidence in both relapsing and primary progressive MS, potentially reshaping the treatment landscape if regulatory approvals follow.